|
|
|
|
TopAbstracts in Congestive Heart Failure 02/04/2010
Recent news - Congestive Heart Failure TopAbstracts in Congestive Heart Failure 01/26/2010- (DGNews) FDA Approves Left Ventricular Assist System for Severe Heart Failure Patients- (DGNews) TopAbstracts in Congestive Heart Failure 01/07/2010- (DGNews)...
|
|
|
Gas Links With Disease Unfounded
Renewed concerns that the fumigation of logs and lumber might be linked to motor neurone disease have no scientific basis, says the forest industry.?Methyl bromide gas is obviously toxic at the doses used to fumigate logs. But outside fumigation envelopes...
|
|
|
Albemarle Announces Strategic Supply Agreement And Settlement & Cross-License Agreement With Chemtura
- Albemarle Corporation announced that it has entered into a series of strategic agreements with Chemtura Corporation.The parties entered into a long-term supply agreement under which Albemarle will supply Chemtura with certain requirements of BA-59P(TM) ...
|
|
|
FDA Finds No Increased Risk of MI, Stroke With Use of Tiotropium Bromide Inhalation Powder
-- The US Food and Drug Administration (FDA) has announced that data from a recent review of tiotropium bromide inhalation powder (Spiriva HandiHaler), a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD), do not support an...
|
|
|
FDA Finds No Increased Risk of MI, Stroke With Use of Tiotropium Bromide Inhalation Powder
my personal edition> copd > news E-Mail this DGNews to a colleague DGNews ROCKVILLE, Md -- January 14, 2010 -- The US Food and Drug Administration (FDA) has announced that data from a recent review of tiotropium bromide inhalation powder (Spiriva...
|
|
|
Ipratropium Bromide for COPD May Up Cardiovascular Risks
FRIDAY, Jan.8 (HealthDay News) -- The use of the short-acting anticholinergic ipratropium bromide for chronic obstructive pulmonary disease (COPD) within the past six months increases the risk of a cardiovascular event (CVE), while the long-acting...
|
|
|
Medical News: Forest And Almirall Announce Positive Results From The ACCORD COPD I Phase III Study Of Aclidinium Bromide In Chronic Obstructive Pulmonary Disease
Forest Laboratories, Inc.(NYSE: FRX) and Almirall, S.A. (ALM.MC) today announced positive top-line results from ACCORD COPD I, a three-month Phase III study comparing aclidinium 200g and 400g BID versus placebo. Aclidinium bromide produced statistically...
|
|
|
Forest And Almirall Announce Positive Results From The ACCORD COPD I Phase III Study Of Aclidinium Bromide In
Forest Laboratories, Inc.(NYSE: FRX) and Almirall, S.A. (ALM.MC) today announced positive top-line results from ACCORD COPD I, a three-month Phase III study comparing aclidinium 200g and 400g BID versus placebo. Aclidinium bromide produced statistically...
|
|
|
Ipratropium Bromide May Increase Risk For Cardiovascular Events
Patients taking ipratropium bromide, an anticholinergic used in the treatment of COPD, may be at an increased risk for cardiovascular events (CVE), including heart failure.Researchers from the University of Washington in Seattle, WA, and Hines VA Hospital in...
|
|
|
Medical News: Ipratropium Bromide May Increase Risk For Cardiovascular Events
Patients taking ipratropium bromide, an anticholinergic used in the treatment of COPD, may be at an increased risk for cardiovascular events (CVE), including heart failure.Medical News: Ipratropium Bromide May Increase Risk For Cardiovascular Events.<...
|
|
|
Ipratropium Bromide May Increase Risk for Cardiovascular Events
-- Patients taking ipratropium bromide for the treatment of chronic obstruction pulmonary disease (COPD) may be at an increased risk for cardiovascular events (CVE), including heart failure.Studies have suggested an increased risk of cardiovascular morbidity...
|
